drugset / Trial / NCT05503901

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT05503901

Phase 3 Completed 131 enrolled Santen Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate safety and the ocular hypotensive effect of STN1012600 ophthalmic solution 0.002% alone or in combination with Timolol ophthalmic solution 0.5% for 52 weeks in subjects with open angle glaucoma or ocular hypertension.

Timeline

Start
2022-08-08
Primary completion
2024-01-30
Completion
2024-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sepetaprost Small molecule 0.002 % Other
Subject Timolol Other / unclassified 0.5 % Other

Indications